Gene therapy and cardiovascular disease

Current Opinion in Cardiology

Volumn 13, Issue 3, 1998, Pages 205-213

  French, Brent A ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; GENE THERAPY; GRAFT REJECTION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICAL PRACTICE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RESTENOSIS; REVIEW; SOMATIC CELL; THROMBOSIS;

CARDIOVASCULAR DISEASES; GENE THERAPY; HUMANS; PROGNOSIS;

EID: 0031781775     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF: Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996, 348:370-374.
2. Friedmann T: Overcoming the obstacles to gene therapy. Sci Am 1997, 276:96-101. This excellent review article provides not only an introduction to gene therapy, but also an overview of current obstacles and steps being taken to overcome them.
3. Felgner PL, Rhodes G: Gene therapeutics. Nature 1991, 349:351-352.
4. Schnieke AE, Kind AJ, Ritchie WA, Mycock K, Scott AR, Ritchie M, Wilmut I, Colman A, Campbell KH: Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. Science 1997, 278:2130-2133.
5. Feigner PL: Nonviral strategies for gene therapy. Sci Am 1997, 276:102-106.
6. Stephan DJ, Yang ZY, San H, Simari RD Wheeler CJ, Feigner PL, Gordon D, Nabel GJ, Nabel EG: A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo. Hum Gene Ther 1996, 7:1803-1812.
7. French BA, Mazur W, Ali NM, Geske RS, Finnigan JP, Rodgers GP, Roberts R, Raizner AE: Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation 1994, 90:2402-2413.
8. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G, Libby P, Dichek DA: Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1995, 96:2955-2965.
9. Rolling F, Samulski RJ: AAV as a viral vector for human gene therapy: generation of recombinant virus. Mol Biotechnol 1995, 3:9-15.
10. Rader DJ: Gene therapy for atherosclerosis. Int J Clin Lab Res 1997, 27:35-43.
11. Gerard RD, Chan L: Adenovirus-mediated gene transfer: strategies and applications in lipoprotein research. Curr Opin Lipidol 1996, 7:105-111.
12. Raper SE, Grossman M, Rader DJ, Thoene JG, Clark BJ 3rd, Kolansky DM, Muller DW, Wilson JM: Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann Surg 1996, 223:116-126.
13. Tsukamoto K, et al.: Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice. J Clin Invest 1997, 100:107-114. This study demonstrates the utility of second-generation Ad5 vectors to mediate prolonged expression of the three human isoforms of apoE and shows that the apoE2 isoform is significantly less efficient than the apoE3 or apoE4 isoforms at clearing remnant lipoproteins in apoE-deficient mice fed a Western diet.
14. Menger MD, Vollmar B: Adhesion molecules as determinants of disease: from molecular biology to surgical research. Br J Surg 1996, 83:588-601.
15. Sen CK, Packer L: Antioxidant and redox regulation of gene transcription. FASEB J 1996, 10:709-720.
16. Radomski MW, Salas E: Nitric oxide-biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Atherosclerosis 1995, 118(suppl):S69-80.
17. Feldman LJ, Isner JM: Gene therapy for the vulnerable plaque. J Am Coll Cardiol 1995, 26:826-835.
18. Rade JJ, Schulick AH, Virmani R, Dichek DA: Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med 1996, 2:293-298.
19. Carmeliet P, Moons L, Dewerchin M, Mackman N, Luther T, Breier G, Ploplis V, Muller M, Nagy A, Plow E, Gerard R, Edgington T, Risau W, Collen D: Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N Y Acad Sci 1997, 811:191-206.
20. Carmeliet P, Stassen JM, Van Vlaenderen I, Meidell RS, Collen D, Gerard RD: Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice. Blood 1997, 90:1527-1534 This study examines the effect of Ad5-mediated tissue plasminogen activator (t-PA) gene transfer in t-PA-deficient and plasminogen activator inhibitor (PAI)-1-overexpressing mice. Although t-PA gene expression subsided within 7 days, it effectively increased plasma fibrinolytic activity-restoring thrombolytic capacity in t-PA-deficient mice and augmenting thrombolytic capacity in PAI-1-overexpressing mice.
21. Harrell RL, Rajanayagam S, Doanes AM, Guzman RJ, Hirschowitz EA, Crystal RG, Epstein SE, Finkel T: Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation 1997, 96:621-627.
22. Simari RD, San H, Rekhter M, Ohno T, Gordon D, Nabel GJ, Nabel EG: Regulation of cellular proliferation and intimai formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest 1996, 98:225-235.
23. Yang ZY, Simari RD, Perkins ND, San H, Gordon D, Nabel GJ, Nabel EG: Role of the p21 cyclin-dependent kinase inhibitor in limiting intimai cell proliferation in response to arterial injury. Proc Natl Acad Sci U S A 1996, 93:7905-7910.
24. Chen D, Krasinski K, Sylvester A, Chen J, Nisen PD, Andres V: Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J Clin Invest 1997, 99:2334-2341.
25. Steg PG, Tahlil O, Aubailly N, Caillaud JM, Dedieu JF, Berthelot K, LeRoux A, Feldman L, Perricaudet M, Denefle P, Branellec D: Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Circulation 1997, 96:408-411.
26. Tahlil O, Brami M, Feldman U, Branellec D, Steg PG: The Dispatch catheter as a delivery tool for arterial gene transfer. Cardiovasc Res 1997, 33:181-187.
27. Schulick AH, Vassalli G, Dunn PF, Dong G, Rade JJ, Zamarron C, Dichek DA: Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries: potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest 1997, 99:209-219. This study is particularly important because it identifies an important obstacle limiting the clinical utility of first-generation Ad5 vectors and examines two approaches to overcoming this obstacle: immunosuppression and extinguishing the residual expression of viral genes.
28. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM: Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996, 3:137-144.
29. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL: A helper-dependent adenovirus vector system: removal of helper virus by Cremediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996, 93:13565-13570. This study is important because it describes an efficient method for producing second-generation Ad5 vectors essentially devoid of any Ad5 genes.
30. Leor J, Quinones MJ, Patterson M, Kedes L, Kloner RA: Adenovirus-mediated gene transfer into infarcted myocardium: feasibility, timing, and location of expression. J Mol Cell Cardiol 1996, 28:2057-2067.
31. Murry CE, Kay MA, Bartosek T, Hauschka SD, Schwartz SM: Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD. J Clin Invest 1996, 98:2209-2217. This study describes an attempt to redirect infarcted myocardium to form skeletal muscle instead of scar tissue by injecting an Ad5 vector carrying a myogenic determination gene (MyoD) into cardiac granulation tissue. When reparative tissue was treated at high dose, the MyoD gene induced the expression of other muscle-specific genes (myogenin and embryonic skeletal MHC), suggesting a strategy that might eventually provide new contractile tissue to repair myocardial infarcts.
32. Schneider MD: Myocardial infarction as a problem of growth control: cell cycle therapy for cardiac myocytes? J Card Fail 1996, 2:259-263.
33. Li Q, Bolli R, Qiu Y, Tang X-L, Willer SS, Murphree SS, French BA: Gene therapy with extracellular superoxide dismutase alleviates myocardial stunning in conscious rabbits [abstract]. Circulation 1997, 96:1-741.
34. Dzau VJ, Horiuchi M: In vivo gene transfer and gene modulation in hypertension research. Hypertension 1996, 28:1132-1137.
35. Chen LM, Chao L, Chao J: Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. Hum Gene Ther 1997, 8:341-347.
36. Niranjan V, Telemaque S, deWit D, Gerard RD, Yanagisawa M: Systemic hypertension induced by hepatic overexpression of human preproen-dothelin-1 in rats. J Clin Invest 1996, 98:2364-2372. This study examines the effect of injecting an Ad5 vector expressing human preproendothelin-1 (preproET-1) into the caudal vein of rats. After 4 days, hepatic overexpression of preproET-1 caused a sixfold elevation in circulating plasma ET-1 levels and a 28 mm Hg increase in mean arterial blood pressure. Intravenous infusion of an ET(A) receptor antagonist reduced blood pressure in these rats, indicating that endogenous overexpression of preproET-1 can cause systemic hypertension through the activation of the ET(A) receptor.
37. Schiffrin EL, Deng LY, Sventek P, Day R: Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens 1997, 15:57-63.
38. Shan K, Kurrelmeyer K, Seta Y, Wang F, Dibbs Z, Deswal A, Lee-Jackson D, Mann DL: The role of cytokines in disease progression in heart failure. Curr Opin Cardiol 1997, 12:218-223.
39. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM: Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997, 81:627-635.
40. Kolls JK, Lei D, Nelson S, Summer WR, Greenberg S, Beutler B: Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J Infect Dis 1995, 171:570-575.
41. Nuss HB, Johns DC, Kaab S, Tomaselli GF, Kass D, Lawrence JH, Marban E: Reversal of potassium channel deficiency in cells from failing hearts by adenoviral gene transfer: a prototype for gene therapy for disorders of cardiac excitability and contractility. Gene Ther 1996, 3:900-912.
42. Hajjar RJ, Kang JX, Gwathmey JK, Rosenzweig A: Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation 1997, 95:423-429. This study used an Ad5 vector to overexpress the sarcoplasmic reticulum calcium ATPase (SERCA2a) in neonatal rat myocytes and found alterations in intracellular calcium handling that resulted in enhanced contraction as measured by cell shortening measurements.
43. Lee J, Laks H, Drinkwater DC, Blitz A, Lam L, Shiraishi Y, Chang P, Drake TA, Ardehali A: Cardiac gene transfer by intracoronary infusion of adenovirus vector-mediated reporter gene in the transplanted mouse heart. J Thorac Cardiovasc Surg 1996, 111:246-252.
44. Brauner R, Wu L, Laks H, Nonoyama M, Scholl F, Shvarts O, Berk A, Drinkwater DC Jr, Wang JL: Intracoronary gene transfer of immunosuppressive cytokines to cardiac allografts: method and efficacy of adenovirus-mediated transduction. J Thorac Cardiovasc Surg 1997, 113:1059-1066. This study examined the effects of several parameters important to Ad5-mediated gene transfer during cold preservation and demonstrated the expression of both TGF-β and viral interleukin-10 in a rabbit model of heterotopic heart transplantation.
45. Qin L, Chavin KD, Ding Y, Tahara H, Favaro JP, Woodward JE, Suzuki T, Robbins PD, Lotze MT, Bromberg JS: Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival. J Immunol 1996, 156:2316-2323.
46. Kato K, Shimozato O, Hoshi K, Wakimoto H, Hamada H, Yagita H, Okumura K: Local production of the p40 subunit of interleukin 12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection. Proc Natl Acad Sci U S A 1996, 93:9085-9089.